Screener Summaries Updates Institutions Sign In More Updates › Other Events › BIAF Other Events · Jul 7, 2026
On July 7, 2026, bioAffinity Technologies, Inc. announced that commercial sales for its noninvasive lung cancer… BIAF bioAffinity Technologies, Inc.
On July 7, 2026, bioAffinity Technologies, Inc. announced that commercial sales for its noninvasive lung cancer diagnostic, CyPath® Lung, have grown by more than 200% year-over-year. The company operates in the biotechnology industry and develops diagnostic tests for cancer.
More from bioAffinity Technologies, Inc. bioAffinity to present investigational sputum-based test data for asthma and COPD at CHEST 2026 Oct 13, 2026 BioAffinity raises $4M via registered direct offering at $6.122 per share Oct 9, 2026 bioAffinity Technologies received written notice from Nasdaq confirming it has regained compliance with the Minimum… Sep 9, 2026 bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize… Jul 22, 2026 bioAffinity Technologies, Inc. consummated a best efforts public offering of 1,040,000 shares of common stock at $0.80… Jun 18, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
